Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (24)

2024

  1. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain

    Clinical and Translational Science, Vol. 17, Núm. 1

2023

  1. 'Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation' by Ali et al. - reassess the evidence, shall we?

    Pharmacogenetics and genomics, Vol. 33, Núm. 4, pp. 88-89

  2. Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers

    Journal of Personalized Medicine, Vol. 13, Núm. 3

  3. “Pharmacogenetics of siponimod: A systematic review” by Díaz-Villamarín et al. – Information is power

    Biomedicine and Pharmacotherapy

2022

  1. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives

    Pharmaceutics, Vol. 14, Núm. 3

2021

  1. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin

    Frontiers in Pharmacology, Vol. 12

  2. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

    Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270

  3. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers

    Biomedicine and Pharmacotherapy, Vol. 133

  4. PriME-PGX: La Princesa university hospital multidisciplinary initiative for the implementation of pharmacogenetics

    Journal of Clinical Medicine, Vol. 10, Núm. 17

2020

  1. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran

    Advances in Therapy, Vol. 37, Núm. 8, pp. 3537-3550

  2. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19)

    Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1023-1033

  3. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers

    Pharmacogenomics Journal, Vol. 20, Núm. 2, pp. 235-245

2019

  1. Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally

    Advances in Therapy, Vol. 36, Núm. 10, pp. 2744-2755

  2. Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure

    Clinical Pharmacology and Therapeutics, Vol. 105, Núm. 3, pp. 661-671

  3. Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 449-455

  4. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 3, pp. 321-329

  5. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics

    Journal of Psychopharmacology, Vol. 33, Núm. 4, pp. 522-531

2018

  1. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 122, Núm. 5, pp. 501-511

  2. Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis

    British Journal of Dermatology

  3. Histone modifications associated with biological drug response in moderate-to-severe psoriasis

    Experimental Dermatology, Vol. 27, Núm. 12, pp. 1361-1371